Research programme: Ubiquitin-protein-ligase-expression-inhibitors - Kronos Bio
Alternative Names: E3 ligases degraders - Kronos BioLatest Information Update: 28 Dec 2023
At a glance
- Originator Kronos Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action Ubiquitin-protein ligase expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for research development in Cancer in USA
- 21 Nov 2019 Early research in Cancer in USA (unspecified route) before November 2019